S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
NASDAQ:GNPX

Genprex (GNPX) Stock Price, News & Analysis

$2.73
-0.01 (-0.36%)
(As of 03/27/2024 ET)
Today's Range
$2.51
$2.90
50-Day Range
$2.73
$10.84
52-Week Range
$2.50
$46.00
Volume
50,308 shs
Average Volume
83,023 shs
Market Capitalization
$4.07 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00

Genprex MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
266.3% Upside
$10.00 Price Target
Short Interest
Bearish
5.58% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.78
Upright™ Environmental Score
News Sentiment
0.44mentions of Genprex in the last 14 days
Based on 9 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($19.60) to ($14.00) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.23 out of 5 stars

GNPX stock logo

About Genprex Stock (NASDAQ:GNPX)

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) that is in Phase 1/2 and 2 clinical trials to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002 for the treatment of type 1 diabetes, and GPX-003 for the treatment of type 2 diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

GNPX Stock Price History

GNPX Stock News Headlines

[BUY ALERT] Our #1 A.I. Stock for March
It's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.
[BUY ALERT] Our #1 A.I. Stock for March
It's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.
Genprex To Expand Non-clinical Program To Study TUSC2, NPRL2
Genprex Provides Business Update and Outlook for 2024
See More Headlines
Receive GNPX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genprex and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
4/01/2019
Today
3/27/2024
Next Earnings (Estimated)
3/29/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:GNPX
Fax
N/A
Employees
31
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.00
High Stock Price Target
$10.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+266.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-23,740,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$18.55 per share

Miscellaneous

Free Float
1,315,000
Market Cap
$4.07 million
Optionable
Optionable
Beta
-0.57
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Mr. John Rodney Varner (Age 67)
    Co-Founder, Chairman, President & CEO
    Comp: $886.97k
  • Mr. Ryan M. Confer M.S. (Age 42)
    Chief Financial Officer
    Comp: $606.57k
  • Mr. David M. Schloss
    Senior Vice President of Human Resources
  • Mr. Thomas C. Gallagher Esq.
    Senior Vice President of Intellectual Property & Licensing
  • Dr. Mark S. Berger M.D. (Age 69)
    Chief Medical Officer
  • Dr. Suzanne Thornton-Jones
    Senior Vice President of Regulatory Affairs & Quality
  • Dr. Jack A. Roth F.A.C.S.
    M.D., Chairman of Scientific & Medical Advisory Board

GNPX Stock Analysis - Frequently Asked Questions

Should I buy or sell Genprex stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Genprex in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" GNPX shares.
View GNPX analyst ratings
or view top-rated stocks.

What is Genprex's stock price target for 2024?

1 brokerages have issued twelve-month target prices for Genprex's stock. Their GNPX share price targets range from $10.00 to $10.00. On average, they predict the company's stock price to reach $10.00 in the next year. This suggests a possible upside of 266.3% from the stock's current price.
View analysts price targets for GNPX
or view top-rated stocks among Wall Street analysts.

How have GNPX shares performed in 2024?

Genprex's stock was trading at $9.20 on January 1st, 2024. Since then, GNPX shares have decreased by 70.3% and is now trading at $2.73.
View the best growth stocks for 2024 here
.

Are investors shorting Genprex?

Genprex saw a increase in short interest in March. As of March 15th, there was short interest totaling 80,300 shares, an increase of 23.7% from the February 29th total of 64,900 shares. Based on an average daily trading volume, of 77,100 shares, the days-to-cover ratio is presently 1.0 days. Currently, 5.6% of the company's stock are sold short.
View Genprex's Short Interest
.

When is Genprex's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 29th 2024.
View our GNPX earnings forecast
.

How were Genprex's earnings last quarter?

Genprex, Inc. (NASDAQ:GNPX) announced its quarterly earnings data on Monday, April, 1st. The company reported ($9.20) EPS for the quarter, missing analysts' consensus estimates of ($5.40) by $3.80.

When did Genprex's stock split?

Shares of Genprex reverse split on the morning of Friday, February 2nd 2024. The 1-40 reverse split was announced on Friday, February 2nd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 2nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of Genprex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Genprex investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Vaxart (VXRT), Tonix Pharmaceuticals (TNXP), Co-Diagnostics (CODX), OPKO Health (OPK), SCYNEXIS (SCYX), iBio (IBIO) and Advanced Micro Devices (AMD).

Who are Genprex's major shareholders?

Genprex's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Catherine M Vaczy and John Rodney Varner.
View institutional ownership trends
.

How do I buy shares of Genprex?

Shares of GNPX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GNPX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners